Objectives: To investigate serum uric as an indicator of fetomaternal complicationsin women with late pregnancy. Study Design: Cross sectional study. Setting: Shalamar Medicaland Dental College Lahore ethical committee. Period: One year from October 2016 to October2017. Methodology: Continuous variables were presented as mean and standard deviationlike age and Serum malonaladehyde concentration; categorical variables were presented asnumbers and percentages like intra uterine growth restriction, Mild to moderate and sever preeclampsia and fetal distress. One way ANOVA, independent sample t test and chi square testwere applied to check significance of results, p value less than or equal to 0.05 was consideredas significant. Results: Overall, 100% (n=400) patients were included in this study. The meanage of the patients was 25.81±4.33 years. The age difference was not statistically significant,in groups (p=0.383). The mean serum uric acid levels of the patients for maturity (weeks)36, 37, 38, 39 and 40 was 247.96±2.52 (nmol/l), 253.95±2.04 (nmol/l), 261.19±3.15 (nmol/l),263.95±2.75 (nmol/l) and 296.19±2.55 (nmol/l) respectively. The differences were statisticallysignificant (p=0.000). Fetal distress, number with rising levels were (n=23) 71.8%, number withno change in levels were (n=3) 9.4% and number with falling levels were (n=6) 18.8%. Thedifferences were statistically significant. (p=0.000). Conclusion: The observations of our studyconcluded that serial increase of serum uric acid from 36th week to 40th week was observedin pregnancy induced hypertion patients, and raised serum level of uric acid had significantrelation with fetomaternal complications. like Fetal distress, preeclampsia, and intrauterinegrowth retardation. So serum uric acid can be used an indicator for fetometernal complicationsin late pregnancy.
To investigate serum uric as an indicator of fetomaternal complications in women with late pregnancy. Study Design: Cross sectional study. Setting: Shalamar Medical and Dental College Lahore ethical committee. Period: One year from October 2016 to October 2017. Methodology: Continuous variables were presented as mean and standard deviation like age and Serum malonaladehyde concentration; categorical variables were presented as numbers and percentages like intra uterine growth restriction, Mild to moderate and sever pre eclampsia and fetal distress. One way ANOVA, independent sample t test and chi square test were applied to check significance of results, p value less than or equal to 0.05 was considered as significant. Results: Overall, 100% (n=400) patients were included in this study. The mean age of the patients was 25.81±4.33 years. The age difference was not statistically significant, in groups (p=0.383). The mean serum uric acid levels of the patients for maturity (weeks) 36, 37, 38, 39 and 40 was 247.96±2.52 (nmol/l), 253.95±2.04 (nmol/l), 261.19±3.15 (nmol/l), 263.95±2.75 (nmol/l) and 296.19±2.55 (nmol/l) respectively. The differences were statistically significant (p=0.000). Fetal distress, number with rising levels were (n=23) 71.8%, number with no change in levels were (n=3) 9.4% and number with falling levels were (n=6) 18.8%. The differences were statistically significant. (p=0.000). Conclusion: The observations of our study concluded that serial increase of serum uric acid from 36 th week to 40 th week was observed in pregnancy induced hypertion patients, and raised serum level of uric acid had significant relation with fetomaternal complications. like Fetal distress, preeclampsia, and intrauterine growth retardation. So serum uric acid can be used an indicator for fetometernal complications in late pregnancy.
No abstract
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.